Stocks · News reference
Bruker Acquires The DISQVER Clinical Metagenomics Platform From Noscendo; Financial Terms Not Disclosed
The DISQVER® platform provides advanced bioinformatics and reporting to support rapid and comprehensive WGS analysis directly from cell-free human blood samplesDISQVER® enables metagenomic next-generation sequencing
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 15, 2026, 11:05 AM
- Checked
- Jul 15, 2026, 11:05 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Bruker shares are trading higher after the company announced a majority investment in MIMETAS to expand its post‑genomic solutions and advance drug discovery through microphysiological systems.
Read original at benzingaBruker Announces Majority Investment In Organ-On-A-Chip Developer MIMETAS, Expanding Into Microphysiological Systems For Drug Discovery; Terms Not Disclosed
Read original at benzingaCitigroup Maintains Neutral on Bruker, Lowers Price Target to $53
Citigroup analyst Brendan Digan maintains Bruker (NASDAQ:BRKR) with a Neutral and lowers the price target from $60 to $53.
Read original at benzinga